BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 27705947)

  • 1. MiRNA203 suppresses the expression of protumorigenic STAT1 in glioblastoma to inhibit tumorigenesis.
    Yang CH; Wang Y; Sims M; Cai C; He P; Yue J; Cheng J; Boop FA; Pfeffer SR; Pfeffer LM
    Oncotarget; 2016 Dec; 7(51):84017-84029. PubMed ID: 27705947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
    Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
    Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
    Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M
    Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-1 suppresses glioblastoma in preclinical models by targeting fibronectin.
    Yang CH; Wang Y; Sims M; Cai C; Pfeffer LM
    Cancer Lett; 2019 Nov; 465():59-67. PubMed ID: 31491450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo.
    Chakrabarti M; Ray SK
    Apoptosis; 2016 Mar; 21(3):312-28. PubMed ID: 26573275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
    Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
    Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
    Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
    Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of long non-coding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152.
    Yao Y; Ma J; Xue Y; Wang P; Li Z; Liu J; Chen L; Xi Z; Teng H; Wang Z; Li Z; Liu Y
    Cancer Lett; 2015 Apr; 359(1):75-86. PubMed ID: 25578780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-124 suppresses glioblastoma growth and potentiates chemosensitivity by inhibiting AURKA.
    Qiao W; Guo B; Zhou H; Xu W; Chen Y; Liang Y; Dong B
    Biochem Biophys Res Commun; 2017 Apr; 486(1):43-48. PubMed ID: 28242198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR‑203 regulates the proliferation, apoptosis and cell cycle progression of pancreatic cancer cells by targeting Survivin.
    Xu D; Wang Q; An Y; Xu L
    Mol Med Rep; 2013 Aug; 8(2):379-84. PubMed ID: 23732815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-106b-5p boosts glioma tumorigensis by targeting multiple tumor suppressor genes.
    Liu F; Gong J; Huang W; Wang Z; Wang M; Yang J; Wu C; Wu Z; Han B
    Oncogene; 2014 Oct; 33(40):4813-22. PubMed ID: 24166509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interference with PSMB4 Expression Exerts an Anti-Tumor Effect by Decreasing the Invasion and Proliferation of Human Glioblastoma Cells.
    Cheng YC; Tsai WC; Sung YC; Chang HH; Chen Y
    Cell Physiol Biochem; 2018; 45(2):819-831. PubMed ID: 29414809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
    Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H
    Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P144, a Transforming Growth Factor beta inhibitor peptide, generates antitumoral effects and modifies SMAD7 and SKI levels in human glioblastoma cell lines.
    Gallo-Oller G; Vollmann-Zwerenz A; Meléndez B; Rey JA; Hau P; Dotor J; Castresana JS
    Cancer Lett; 2016 Oct; 381(1):67-75. PubMed ID: 27473823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal.
    Lulli V; Buccarelli M; Martini M; Signore M; Biffoni M; Giannetti S; Morgante L; Marziali G; Ilari R; Pagliuca A; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
    Oncotarget; 2015 Nov; 6(35):37241-56. PubMed ID: 26437223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-101 inhibits proliferation, migration and invasion of human glioblastoma by targeting SOX9.
    Liu N; Zhang L; Wang Z; Cheng Y; Zhang P; Wang X; Wen W; Yang H; Liu H; Jin W; Zhang Y; Tu Y
    Oncotarget; 2017 Mar; 8(12):19244-19254. PubMed ID: 27911279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer.
    Li M; Chen W; Zhang H; Zhang Y; Ke F; Wu X; Zhang Y; Weng M; Liu Y; Gong W
    Oncotarget; 2016 Dec; 7(50):83060-83070. PubMed ID: 27825112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient delivery of anti-miR-210 using Tachyplesin, a cell penetrating peptide, for glioblastoma treatment.
    Jana A; Narula P; Chugh A; Kulshreshtha R
    Int J Pharm; 2019 Dec; 572():118789. PubMed ID: 31726199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
    Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
    Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.